Cisplatin (Platinol ®)
Hyperthermic Intrathoracic Chemotherapy (HITOC) after Cytoreductive Surgery for Pleural Malignancies-A Retrospective, Multicentre Study
Cancers 2021 September 12 [Link] Michael Ried, Julia Kovács, Till Markowiak, Karolina Müller, Gunnar Huppertz, Michael Koller, Hauke Winter, Laura V Klotz, Rudolf Hatz, Julia Zimmermann, Bernward Passlick, Severin Schmid, Mohamed Hassan, Martin E Eichhorn, Hans-Stefan Hofmann Abstract In the context of quality assurance, the objectives were to describe the surgical treatment and postoperative morbidity…
Read MoreHyperthermic Intrathoracic Chemotherapy (HITOC) after Cytoreductive Surgery for Pleural Malignancies-A Retrospective, Multicentre Study
Cancers 2021 September 12 [Link] Michael Ried, Julia Kovács, Till Markowiak, Karolina Müller, Gunnar Huppertz, Michael Koller, Hauke Winter, Laura V Klotz, Rudolf Hatz, Julia Zimmermann, Bernward Passlick, Severin Schmid, Mohamed Hassan, Martin E Eichhorn, Hans-Stefan Hofmann Abstract In the context of quality assurance, the objectives were to describe the surgical treatment and postoperative morbidity…
Read MoreGemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial
The Lancet Oncology 2021 September 6 [Link] Carmine Pinto, Paolo Andrea Zucali, Maria Pagano, Federica Grosso, Giulia Pasello, Marina Chiara Garassino, Marcello Tiseo, Hector Soto Parra, Francesco Grossi, Federico Cappuzzo, Filippo de Marinis, Paolo Pedrazzoli, Maria Bonomi, Letizia Gianoncelli, Matteo Perrino, Armando Santoro, Francesca Zanelli, Candida Bonelli, Antonio Maconi, Stefano Frega, Erika Gervasi, Luca Boni,…
Read MoreManagement of Advanced Pleural Mesothelioma-At the Crossroads
JCO Oncology Practice 2021 September 7 [Link] Anna K Nowak, Alannah Jackson, Calvin Sidhu Abstract The management of pleural mesothelioma has changed with the demonstration that first-line checkpoint blockade therapy improves survival. This review covers issues of relevance to the practicing medical oncologist, with an emphasis on the palliative setting and on new information. Until…
Read MoreTumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models
Lung Cancer 2021 August 27 [Link] Helena Mumblat, Antonia Martinez-Conde, Ori Braten, Mijal Munster, Eyal Dor-On, Rosa S Schneiderman, Yaara Porat, Tali Voloshin, Shiri Davidi, Roni Blatt, Anna Shteingauz, Catherine Tempel-Brami, Einav Zeevi, Carolina Lajterer, Yuval Shmueli, Shiri Danilov, Adi Haber, Moshe Giladi, Uri Weinberg, Adrian Kinzel, Yoram Palti Abstract Objectives: Tumor Treating Fields (TTFields)…
Read MoreMitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment: a retrospective study
Translational lung Cancer Research 2021 July [Link] Alexander Mathilakathu, Sabrina Borchert, Michael Wessolly, Elena Mairinger, Hendrik Beckert, Julia Steinborn, Thomas Hager, Daniel C Christoph, Jens Kollmeier, Jeremias Wohlschlaeger, Thomas Mairinger, Kurt Werner Schmid, Robert F H Walter, Luka Brcic, Fabian D Mairinger Abstract Background: Malignant pleural mesothelioma (MPM) is a rare malignant tumor associated with…
Read MoreNeoadjuvant pemetrexed plus cisplatin followed by pleurectomy for malignant pleural mesothelioma
Journal of Thoracic and Cardiovascular Surgery 2021 July 17 [Link] Seiki Hasegawa, Kohei Yokoi, Morihito Okada, Fumihiro Tanaka, Mototsugu Shimokawa, Takashi Daimon, Takashi Nakano Abstract Purpose: Despite becoming the preferred surgical technique for malignant pleural mesothelioma, pleurectomy/decortication has received few prospective clinical trials. Therefore, the Japan Mesothelioma Interest Group conducted a prospective multi-institutional study to…
Read MoreComparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma
Lung Cancer 2021 July 17 [Link] Roger Y Kim, Yimei Li, Melina E Marmarelis, Anil Vachani Abstract Objectives: Second-line immune checkpoint inhibition (ICI) was recently shown to have a survival advantage over placebo in malignant pleural mesothelioma (MPM), but the survival comparison to chemotherapy in patients with MPM receiving routine clinical care is unknown. Our…
Read MoreBlocking the GITR-GITRL pathway to overcome resistance to therapy in sarcomatoid malignant pleural mesothelioma
Communications Biology 2021 July 26 [Link] Meilin Chan, Licun Wu, Zhihong Yun, Trevor D McKee, Michael Cabanero, Yidan Zhao, Mikihiro Kohno, Junichi Murakami, Marc de Perrot Abstract Malignant pleural mesothelioma (MPM) is an aggressive neoplasm originating from the pleura. Non-epithelioid (biphasic and sarcomatoid) MPM are particularly resistant to therapy. We investigated the role of the…
Read MoreDetection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification
Cytokine 2021 June 19 [Link] Loredana Urso, Micol Silic-Benussi, Alice Boscolo, Martina Lorenzi, Laura Bonanno, Francesca Lunardi, Valentina Guarneri, Fiorella Calabrese, Federico Rea, PierFranco Conte, Giulia Pasello Abstract Background: No data on circulating biomarkers for the prognostic stratification of Malignant Pleural Mesothelioma (MPM) patients are available. We prospectively explored the prognostic role of circulating monocyte…
Read More